Dai-Hong Liu

List of Publications by Year
in descending order

87 papers	2,402 citations	361045 20 h-index	223531 46 g-index
111 all docs	111 docs citations	111 times ranked	1961 citing authors

#	Article	IF	Citations
1	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	0.6	285
2	Risk stratificationâ€“directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 3256-3262.	0.6	264
3	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in Chinaâ€”recommendations from the Chinese Society of Hematology. Journal of Hematology and Oncology, 2018, 11, 33.	6.9	233
4	Longâ€term followâ€up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer, 2013, 119, 978-985.	2.0	224
5	Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 2007, 92, 414-417.	1.7	147
6	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. Journal of Hematology and Oncology, 2021, 14, 145.	6.9	124
7	Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation. Stem Cells and Development, 2016, 25, 1874-1883.	1.1	123
8	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Letters, 2018, 438, 63-75.	3.2	116
9	Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia. Journal of Clinical Immunology, 2008, 28, 276-283.	2.0	66
10	Prevention of relapse using <scp>DLI</scp> can increase survival following <scp>HLA</scp>â€identical transplantation in patients with advancedâ€stage acute leukemia: a multiâ€center study. Clinical Transplantation, 2012, 26, 635-643.	0.8	56
11	Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplantation, 2021, 56, 2940-2947.	1.3	43
12	Efficacy of Oral Cryotherapy on Oral Mucositis Prevention in Patients with Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0128763.	1.1	41
13	Modified donor lymphocyte infusionâ€associated acute graftâ€versusâ€host disease after haploidentical <scp>T</scp>â€cellâ€replete hematopoietic stem cell transplantation: incidence and risk factors. Clinical Transplantation, 2012, 26, 868-876.	0.8	40
14	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1314-1321.	2.0	36
15	Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget, 2017, 8, 63574-63586.	0.8	32
16	YTHDF2 is a potential target of AML1/ETO-HIF1Î± loop-mediated cell proliferation in t(8;21) AML. Oncogene, 2021, 40, 3786-3798.	2.6	30
17	Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory Cytokines. Biology of Blood and Marrow Transplantation, 2010, 16, 1567-1575.	2.0	28
18	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemiaâ€“Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 929-936.	2.0	28

#	Article	IF	Citations
19	Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. Journal of Experimental and Clinical Cancer Research, 2020, 39, 278.	3.5	27
20	Risk factors and clinical outcomes of Epsteinâ€“Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Annals of Hematology, 2019, 98, 2163-2177.	0.8	26
21	Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. OncoImmunology, 2016, 5, e1139274.	2.1	24
22	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cellâ€“Replete Haploidentical Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1176-1182.	2.0	21
23	The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLAâ€mismatched/haploidentical hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2011, 57, 135-141.	0.8	19
24	Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. Annals of Hematology, 2019, 98, 185-193.	0.8	19
25	Basiliximab for steroidâ€refractory acute graftâ€versusâ€host disease: A realâ€world analysis. American Journal of Hematology, 2022, 97, 458-469.	2.0	19
26	Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies. British Journal of Haematology, 2017, 176, 92-100.	1.2	18
27	Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. Nature Communications, 2019, 10, 5051.	5.8	17
28	Lowâ€dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical <scp>HSCT</scp>. Clinical Transplantation, 2015, 29, 594-605.	0.8	16
29	Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Chinese Medical Journal, 2014, 127, 3602-9.	0.9	16
30	The efficacy and safety of sirolimusâ€based graftâ€versusâ€host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a metaâ€analysis of randomized controlled trials. Transfusion, 2015, 55, 2134-2141.	0.8	14
31	AML1â€“ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia. Experimental Hematology, 2017, 46, 62-69.	0.2	14
32	Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies. Annals of Hematology, 2020, 99, 1883-1893.	0.8	14
33	Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies. PLoS ONE, 2015, 10, e0132620.	1.1	14
34	Interferon Î±: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. Chinese Medical Journal, 2014, 127, 2583-7.	0.9	14
35	Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study. International Journal of Hematology, 2013, 98, 708-715.	0.7	13
36	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	6.9	13

#	Article	IF	Citations
37	Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Annals of Hematology, 2019, 98, 1267-1277.	0.8	12
38	Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Annals of Hematology, 2020, 99, 167-179.	0.8	12
39	Intracranial Hemorrhage and Mortality In 1461 Patients After Allogeneic Hematopoietic Stem Cell Transplantation For 6-Year Follow-Up: Study Of 44 Cases. Blood, 2013, 122, 3322-3322.	0.6	12
40	Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models. Oncotarget, 2016, 7, 61764-61774.	0.8	11
41	Safety of Recombinant Human Thrombopoietin in Adults after Related Donor Haploidentical Haematopoietic Stem Cell Transplantation. Clinical Drug Investigation, 2011, 31, 135-141.	1.1	8
42	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	0.6	8
43	Efficacy and Safety of Unmanipulated Haploidentical Related Donor Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Chinese Medical Journal, 2018, 131, 790-798.	0.9	8
44	Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. Annals of Hematology, 2019, 98, 1237-1247.	0.8	8
45	Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing. Annals of Hematology, 2020, 99, 2611-2617.	0.8	8
46	Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. Cancer Medicine, 2021, 10, 3165-3176.	1.3	8
47	T Cell-Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation for Treatment of T-Lymphoblastic Lymphoma. Annals of Transplantation, 2018, 23, 427-433.	0.5	6
48	Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia . OncoTargets and Therapy, 2019, Volume 12, 5013-5023.	1.0	5
49	The impact of intestinal microbiota in antithymocyte globulinâ€“based myeloablative allogeneic hematopoietic cell transplantation. Cancer, 2022, 128, 1402-1410.	2.0	5
50	Peripheral T-cell Lymphomas. Chinese Medical Journal, 2018, 131, 2105-2111.	0.9	4
51	Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma. Chinese Medical Journal, 2019, 132, 1765-1772.	0.9	4
52	Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2021, 27, 75.e1-75.e10.	0.6	4
53	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. Chinese Medical Journal, 2021, 134, 1299-1309.	0.9	4
54	Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, , .	0.6	4

#	Article	IF	Citations
55	Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Center Experience. Annals of Transplantation, 2017, 22, 58-65.	0.5	3
56	Hydrogen-Rich Water Ameliorates Murine Chronic Graft-versus-Host Disease through Antioxidation. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-8.	1.9	3
57	Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience. Annals of Hematology, 2022, 101, 397-408.	0.8	3
58	Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission. Leukemia and Lymphoma, 2020, 61, 118-127.	0.6	2
59	CD4 + CD25 - CD69 + t Cells Is a Novel Subset of Regulatory T Cells Involved In the Prevention of Acute Graft-Versus-Host Disease In Human. Blood, 2010, 116, 1250-1250.	0.6	1
60	KIT Mutation Versus MRD, Which Is More Important To Predict Relapse Of Acute Myeloid Leukemia With t (8; 21)?. Blood, 2013, 122, 1309-1309.	0.6	1
61	Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study. Blood, 2014, 124, 1231-1231.	0.6	1
62	Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience. Annals of Transplantation, 2019, 24, 367-373.	0.5	1
63	Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial. Blood, 2012, 120, 139-139.	0.6	1
64	Prolonged Thrombocytopenia Is Associated With Increases Of CD8+ CX3CR1+ Cells In The Bone Marrow After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 5494-5494.	0.6	1
65	Myeloid tumors accompanying systemic mastocytosis, basophilia, and abnormal platelet-derived growth factor receptor Î². Medicine (United States), 2021, 100, e24707.	0.4	0
66	HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia.. Blood, 2006, 108, 3154-3154.	0.6	0
67	Partially Matched Related Donor Transplantation Can Achieve Outcomes Comparable to Unrelated Donor Transplantation for Patients with Hematologic Malignancies.. Blood, 2009, 114, 1197-1197.	0.6	0
68	Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. Blood, 2010, 116, 2347-2347.	0.6	0
69	Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation. Blood, 2010, 116, 2312-2312.	0.6	0
70	Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Association with Reduced Ploidy and Immaturation of Megakaryocytes. Blood, 2010, 116, 4695-4695.	0.6	0
71	IL-17-Producing T Cells Contribute to Mediate Acutegraft-Versus-Disease In Patients Undergoing Unmanipulated Blood and MarrowTransplantation. Blood, 2010, 116, 2310-2310.	0.6	0
72	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. Blood, 2011, 118, 4161-4161.	0.6	0

#	Article	IF	Citations
73	Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 659-659.	0.6	0
74	A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4512-4512.	0.6	0
75	Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. Blood, 2013, 122, 1346-1346.	0.6	0
76	Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine and Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission. Blood, 2013, 122, 3290-3290.	0.6	0
77	Rituximab-Based Treatments Followed By Adoptive Cellular Therapies For EBV-Associated Post-Transplant Lymphoproliferative Disease In Recipients Of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4637-4637.	0.6	0
78	Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial. Blood, 2014, 124, 40-40.	0.6	0
79	Allogeneic Halpo-Identical Hematopoietic Stem Cell Transplantation for High-Risk Leukemia. Blood, 2015, 126, 5514-5514.	0.6	0
80	Similar Outcomes of Allogeneic Hematopoietic Cell Transplantation from Matched Sibling Donor and Haploidentical Donor for Refractory/Relapsed Acute Myeloid Leukemia. Blood, 2015, 126, 5511-5511.	0.6	0
81	Similar Incidence of Severe Acute Gvhd and Less Extensive Chronic Gvhd in PBSCT from Unmanipulated Haploidentical Donor Compared with That from Matched Sibling Donor for Patients with Hematologic Malignancies. Blood, 2015, 126, 1964-1964.	0.6	0
82	Haploidentical Unmanipulated G-CSF-Primed Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies. Blood, 2015, 126, 4365-4365.	0.6	0
83	Effect of Transfusion of the Third Party Umbilical Cord Blood on Haplo-Identical Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 1943-1943.	0.6	0
84	The Efficacy of CT-Diagnostic-Driven Antifungal Strategy with Voriconazole for Invasive Aspergillosis in Patients with Hematological Diseases: A Multicenter, Prospective Study. Blood, 2016, 128, 2370-2370.	0.6	0
85	Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia. Chinese Medical Journal, 2017, 130, 127-129.	0.9	0
86	A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT. International Journal of Hematology, 2022, , 1.	0.7	0
87	Increased risk of nonrelapse mortality post Tâ€cellâ€replete haploidentical stem cell transplantation in patients with recurrence of acute graftâ€versusâ€host disease. Hematological Oncology, 2022, 40, 743-751.	0.8	0